Brief: Brickell Biotech Inc Says Final Patient Has Completed Phase 3 Pivotal Cardigan I Study
29/06/2021 21:52
June 29 (Reuters) - Brickell Biotech Inc BBI.O :
* BRICKELL BIOTECH INC - FINAL PATIENT HAS COMPLETED PHASE 3
PIVOTAL CARDIGAN I STUDY
* BRICKELL BIOTECH INC - ALL PLANNED PATIENTS HAVE BEEN
ENROLLED
IN PHASE 3 PIVOTAL CARDIGAN II STUDY
Source text for Eikon: ID:nGNX1vPV22
Further company coverage: BBI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh Tracks Therapeutics
See all newsBrief: Fresh Tracks Therapeutics Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Fresh Tracks Therapeutics Intends To Seek Judicial Dissolution If Liquidation And Approved By Stockholders
Brief: Fresh Tracks Therapeutics Q3 EPS USD 0.32
Brief: Fresh Tracks Therapeutics Inc On October 10 Received A Notice From Listing Qualifications Department Of Nasdaq
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx